Articles tagged with Metastasis
Physicists at Rice University have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The research found a three-way genetic switch that explains previously confusing experimental results, opening new avenues for cancer treatment.
The study identified Wnt5A as a key player in promoting melanoma metastasis and therapy resistance. By understanding the role of Wnt5A, researchers may be able to identify patients who are more likely to respond to BRAF inhibitors and develop new targeted therapies.
Researchers at Princeton University have found that microRNAs can reduce the number of osteoclasts present in bones, inhibiting their forced labor. This could lead to effective treatment targets for tackling bone metastasis and help detect cancer's spread to the bone.
Researchers developed a new approach to selectively permeabilize the blood-brain barrier at sites of brain metastases using tumor necrosis factor. This allows for more effective delivery of anti-breast cancer drugs to brain metastases.
A study found that single-fraction radiotherapy, given in one session, is as effective as multiple-fraction treatment but has lower costs. Patients who received single-fraction treatment had poorer prognoses, but it offers benefits for patient-centric palliative care.
Lihong Wang has received a $3.5 million NIH grant to translate his single-cell label-free photoacoustic microscopy technology into the clinic for cancer screening, detection, prognosis, and monitoring.
Researchers have identified molecular profiles of tumors with unknown primary sites, allowing for more effective treatment and improved survival rates. The study found that the biology of the tumor is more important than its primary site in determining treatment effectiveness.
The TH3RESA trial shows that T-DM1 significantly improves progression-free survival in women with advanced HER2 positive breast cancer, with a nearly three-month increase from 3.3 months to 6.2 months. The treatment also demonstrates a more favorable safety profile compared to standard therapy.
A large-scale analysis of 20,034 patients found that young age is associated with worse overall survival and progression-free survival in those with metastatic colorectal cancer. The study suggests that these patients have a poorer prognosis if their disease has metastasized.
Scientists at EMBL found that cells in a zebrafish embryo determine their direction by erasing the path behind them and creating a self-generated chemokine gradient. This finding could have implications for development, cancer, and metastasis.
Patients under 50 years old have improved OS after SRS, with no greater risk of new brain metastases. SRS alone is a favorable first-line therapeutic option for younger patients.
Researchers developed a microfluidic device to study cancer cell extravasation, the process by which cells escape blood vessels. The device revealed that most arrested cells are trapped and eventually squeeze through, with their nuclei escaping even earlier than expected. Understanding this process can help identify therapies to preven...
Research finds high levels of Fragile X Mental Retardation Protein (FMRP) in human breast tissue correlate with increased risk and spread of breast cancer. FMRP acts as a master regulator controlling aggressive cancer progression.
Researchers identify phosphoinositide-dependent kinase-1 (PDK1) as a critical regulator in melanoma development and metastasis. Inhibiting the PDK1 enzyme delays tumor growth and almost completely abolishes metastasis, offering new therapeutic opportunities for this life-threatening disease.
Researchers found that high levels of miR-200 expression boost survival rates for patients with lung, ovarian, renal, and triple-negative breast cancers. MicroRNAs regulate gene activation and expression, and targeting IL-8 and CXCL1 can inhibit angiogenesis and cancer progression.
Researchers found that certain genes, such as CXCL12 and IGF1, make breast cancer cells more likely to survive in bone tissue by mimicking the environment of their preferred organ. This discovery could lead to new drugs that prevent cancer spread to bone or other organs.
Researchers linked stress gene ATF3 to the spread of breast cancer, finding that immune-system cells expressing ATF3 aid cancer's survival and movement. The study suggests ATF3 may be a master switch enabling cancer's growth and metastasis.
Researchers have direct evidence that epithelial-to-mesenchymal transition (EMT) occurs in human ovarian cancer patients, resulting in unique characteristics and resistance to chemotherapy. This finding highlights the need for combination therapy targeting both primary tumors and metastatic cells.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to the brain. The approach shows significant promise in reducing metastatic brain tumor size, providing new hope for pati...
A new therapeutic approach to treating prostate cancer has been identified through a study on the FoxM1 protein. Depletion of FoxM1 in prostate epithelial cells inhibits tumor cell proliferation, metastasis, and new blood vessel formation.
Researchers at Saint Louis University found that high-dose interleukin-2 (HD IL-2) therapy can improve the life span of melanoma patients with brain metastases. The study, published in Chemotherapy Research and Practice, reviewed cases of eight patients who underwent this treatment.
Researchers discovered a biological mechanism that preserves intestinal tracts in mice treated with lethal doses of chemotherapy, increasing survival rates by up to 75%. The findings could revolutionize cancer therapy by allowing humans to tolerate stronger doses of chemotherapy and radiation, potentially curing later-stage metastasize...
Researchers develop method to filter out cancer cells from cerebrospinal fluid to prevent brain metastasis and decrease complications. This technique may help treat breast cancer and other metastasizing cancers earlier and with potentially fewer drugs.
Scientists have identified a novel gene, mda-9/syntenin, as a potential therapeutic target for bladder cancer. The study showed that the gene helps regulate bladder cancer growth and metastasis, making it a promising target for detecting and monitoring the disease.
Researchers have discovered that cancer cells can fuse with blood cells, enabling them to travel through the body and seed new tumors. This breakthrough has major implications for treating metastatic cancers.
Researchers found that consuming soy peptide lunasin orally reduced the number of metastatic tumors in mice with human colon cancer cells. The highest dose of 20 mg/kg of lunasin achieved a 94% reduction in tumors, showing promise for new cancer treatment approaches.
Removing MerTK from immune cells decreases tumor growth and metastasis in breast, melanoma, and colon cancers. Inhibition of MerTK may stimulate anti-tumor responses and have clinical benefits.
Researchers have identified microRNA-22 as a driver of both cancer onset and metastasis, particularly in breast cancer and blood cancers. The study suggests that inhibiting miR-22 through a 'decoy' method could offer a novel therapeutic option for treating these diseases.
Researchers from Max Planck Institute discovered the P2Y2 receptor molecule on blood platelet walls enables tumor cells to enter organs via blood vessel openings. Blocking this key molecule may lead to new therapeutic approaches for malignant tumors.
Researchers at Yale University found that a human metastatic tumor can arise when a leukocyte and a cancer cell fuse to form a genetic hybrid, potentially explaining how cancer cells travel to distant organs. The study's findings provide the first evidence of such a phenomenon in humans and could lead to new therapy targets.
A new study by RI-MUHC researchers identifies a previously unknown mode of cancer progression, where infection-fighting white blood cells activate cancer cells and facilitate their spread to secondary tumours. Medications already used for other non-cancer diseases may prevent this mechanism of cancer spread or metastasis.
Researchers found that PET-CT improved staging accuracy and intrathoracic disease identification in limited-stage small-cell lung cancer patients. This led to an improvement in overall survival rates compared to those not staged with PET-CT.
A study by University of Notre Dame researchers found that cancer cells use antioxidant enzymes to survive detachment from the extracellular matrix. This discovery may lead to targeted therapies for metastatic cancers.
Researchers found that a developmental protein called ROR1 promotes cancer metastasis by regulating epithelial-mesenchymal transition. Silencing ROR1 reverses this process and inhibits tumor growth in animal models.
A subgroup analysis from a phase III clinical trial found that eribulin demonstrated a greater potential benefit in overall survival compared to capecitabine for women with previously treated metastatic breast cancer. Specifically, patients with multiple organs involved, those who had not received chemotherapy for six months or longer,...
A new hybrid molecular imaging system combines positron emission tomography and magnetic resonance to detect recurrent prostate cancer. The study reveals that PET/MR finds more areas of metastases than PET/CT, making it a viable alternative for restaging patients with metastatic prostate cancer.
Researchers have developed a novel imaging agent, Tc-99m MIP-1404, which binds to PSMA enzyme in prostate cancer cells, enabling detection of metastases. The agent shows promise in detecting lesions more accurately than standard bone imaging.
Researchers at Uni Basel have discovered Sox4 as a key player in cancer metastasis, triggering the epithelial-mesenchymal transition (EMT) process. The study found that Sox4 promotes the expression of genes involved in EMT and metastasis, leading to changes in gene expression and cell behavior.
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
Researchers at University of South Florida found a combination of nontoxic therapies prolonged survival time by 78% in mice with metastatic cancer. The treatment combined ketogenic diet and hyperbaric oxygen therapy, both non-toxic to healthy tissues while damaging cancer cells.
The EORTC BOS 2 trial aims to improve outcomes for patients with resectable liver metastases from colorectal cancer by testing the efficacy of bevacizumab or panitumumab added to standard peri-operative FOLFOX 4 chemotherapy. The trial plans to accrue 360 patients in 50 sites across ten countries.
Researchers at Berkeley Lab identified the microenvironment surrounding microvasculature as a niche where dormant breast tumor cells reside. The study reveals that stable microvasculature suppresses growth and creates a dormant niche, while sprouting neovasculature sparks micrometastatic outgrowth.
A genetic rogue element known as chimeric transcript LCT13 is linked to the silencing of a tumor suppressor gene TFPI-2, promoting cancer invasion and metastasis. The study suggests that 'junk DNA' can interfere with normal cell function, providing new insights into cancer progression.
Researchers have discovered that targeting regulatory T cells can help eliminate cancer cells, while a new fluorescence labeling method enables the visualization of microRNAs in tissue sections. Additionally, studies suggest that malnourishment exacerbates Giardia infection in mice, leading to severe gastrointestinal problems and growt...
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
Researchers at MU College of Veterinary Medicine have created radioactive nanoparticles that target lymphoma tumor cells, a crucial step toward treating metastasized cancers. The nanoparticles, made with lutetium and gold shells, can deliver radiation to tumors without harming healthy cells.
Researchers found that a tumor-activated protein, VEGF-C, activates integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive to metastatic tumor cells. This highlights the way tumors can have long-range effects on other parts of the body, impacting tumor metastasis or growth.
Researchers at Stanford University School of Medicine developed a new technique to visualize cell interactions in living mice, pinpointing metastatic cancer cells' locations after breaking off from initial tumor sites. The method uses light-emitting proteins and has potential applications in studying various cell interactions.
A recent study by Henry Ford Health reveals that prostate cancer patients with metastasis are more likely to die after weekend emergency department visits compared to weekdays. The study found that these patients have a 23% increased likelihood of death after weekend visits, despite being older and healthier on average.
Researchers have discovered that breast cancer patients with dense breasts are more likely to develop aggressive tumors. A protein called DDR2 plays a key role in this process, facilitating the spread of cancer cells by activating a multistep pathway.
Scientists at Weill Cornell Medicine have discovered two key proteins that work to block cancer's spread by generating a microenvironment that prevents cancer cells from settling and growing in distant organs. The study suggests that therapeutic proteins could offer a new treatment strategy for metastatic cancer.
Cancer cells exhibit unique physical properties as they metastasize, including increased deformability and reduced oxygen consumption. This study provides new insights into the dynamics of cancer cell behavior, suggesting that these traits enable them to spread through the body.
Researchers have developed a new way to learn how good cells go bad by studying the mechanical and biochemical behavior of cells simultaneously. This technology combines atomic force microscopy and nuclear magnetic resonance, allowing for detailed insights into disease processes.
Researchers discovered metastasis stem cells in the blood of breast cancer patients, characterized by specific surface molecules CD44, CD47, and MET. These cells are associated with a poorer prognosis and may serve as a promising biomarker for disease progression.
Research finds that palliative radiotherapy significantly improves the quality of life for elderly patients with painful bone metastases. The treatment, which involves a single fraction of radiotherapy, has been shown to be effective in all age groups, including those over 75, despite some variability in response.
A new therapy uses radioactive Listeria bacteria to selectively infect tumor cells and deliver radioisotopes, dramatically decreasing the number of metastases in a mouse model of highly aggressive pancreatic cancer. The treatment also showed promise in reducing metastases by 90% in mice with metastatic pancreatic cancer.
Dr. Susan E. Clare's research aims to deliver chemotherapy directly to brain metastases using immune cells and nanoparticles, targeting HER2 positive and triple negative breast cancers. The system uses nanoshells coated with gold to release drugs at will in the appropriate spot in the brain.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
Researchers found that HIF1 and HIF2 are overexpressed in melanoma tumors, promoting the spread of cancer through the lymphatic system. Suppressing these transcription factors reduced the rate of metastasis in mouse models.
High levels of kisspeptins in aggressive breast cancers increase tumor grade and metastatic potential, according to Western University research. The study suggests that estrogen receptor status may play a role in kisspeptin's unusual behavior, making it a potential diagnostic biomarker for more aggressive breast cancer.